Efficacy was observed in patients with RET-altered locally advanced or metastatic solid tumours, including RET-mutant MTC, previously treated, RET-mutant MTC and RET fusion-positive thyroid cancers. This evidence concerns the gene RET and thyroid gland carcinoma.